Silverarc Capital Management LLC Sells 176,540 Shares of ABIVAX Société Anonyme (NASDAQ:ABVX)

Silverarc Capital Management LLC cut its stake in ABIVAX Société Anonyme (NASDAQ:ABVX - Free Report) by 38.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 285,120 shares of the company's stock after selling 176,540 shares during the quarter. Silverarc Capital Management LLC owned 0.45% of ABIVAX Société Anonyme worth $2,087,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently made changes to their positions in ABVX. GAMMA Investing LLC purchased a new stake in ABIVAX Société Anonyme in the fourth quarter worth approximately $29,000. R Squared Ltd bought a new stake in shares of ABIVAX Société Anonyme in the fourth quarter worth $36,000. Guggenheim Capital LLC bought a new stake in shares of ABIVAX Société Anonyme in the fourth quarter worth $92,000. Springhill Fund Asset Management HK Co Ltd purchased a new stake in ABIVAX Société Anonyme during the fourth quarter valued at $1,520,000. Finally, Kennedy Capital Management LLC lifted its holdings in ABIVAX Société Anonyme by 0.7% in the fourth quarter. Kennedy Capital Management LLC now owns 225,470 shares of the company's stock valued at $1,650,000 after acquiring an additional 1,656 shares during the period. 47.91% of the stock is currently owned by institutional investors.

ABIVAX Société Anonyme Stock Down 1.3 %

Shares of ABVX stock traded down $0.09 on Friday, hitting $6.84. 26,965 shares of the stock traded hands, compared to its average volume of 131,861. ABIVAX Société Anonyme has a 52 week low of $4.77 and a 52 week high of $16.63. The firm has a 50 day simple moving average of $6.65 and a two-hundred day simple moving average of $7.61.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on ABVX shares. Morgan Stanley reaffirmed an "equal weight" rating and set a $12.00 price target on shares of ABIVAX Société Anonyme in a research report on Thursday, March 20th. JMP Securities reissued a "market outperform" rating and set a $33.00 price objective on shares of ABIVAX Société Anonyme in a research report on Friday, January 10th. One research analyst has rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus price target of $38.00.

ABIVAX Société Anonyme Profile

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.